August 25, 2014 3:04 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Achillion Pharma (NASDAQ: ACHN) got a mid-day pop Monday following some bullish comments from UBS's Andrew Peters. The stock rallied more than six percent following the release of the intraday research note, adding onto an already 4.7 percent gain. The UBS analyst believes the Street has been pricing in M&A potential into Achillion shares. Peters had previously viewed InterMune (NASDAQ: ITMN) as the top takeover candidate in the biotech space. Given the premium by Roche and an apparent competitive process, Peters highlighted a scarcity of de-risked assets. Peters maintains a Buy rating and $11 price target on shares of Achillion. The stock last traded at $10.80, up more than 10.5 percent for Monday's session.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.